miR-622 suppresses tumor formation by directly targeting VEGFA in papillary thyroid carcinoma
Authors Wang R, Ma Q, Ji L, Yao Y, Ma M, Wen Q
Received 12 November 2017
Accepted for publication 12 January 2018
Published 16 March 2018 Volume 2018:11 Pages 1501—1509
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 3
Editor who approved publication: Dr Yao Dai
Renjie Wang, Qingjie Ma,* Linlin Ji, Yue Yao, Mengshi Ma, Qiang Wen*
Department of Nuclear Medicine, China–Japan Union Hospital of Jilin University, Changchun, People’s Republic of China
*These authors contributed equally to this work
Background: MicroRNAs (miRNAs) were reportedly to play crucial roles in papillary thyroid carcinoma (PTC) tumorigenesis and development. Therefore, the discovery of miRNAs may provide a new and powerful tool for diagnosis and treatment of PTC.
Purpose: The aim of this study was to investigate the biological function and underlying mechanism of miR-622 in PTC.
Materials and methods: The expression levels of miR-622 in PTC patient tissues and cell lines were determined by quantitative RT-PCR (qRT-PCR). The biological function including cell proliferation, colony formation, migration and invasion, as well as underling mechanism of miR-622 in PTC, were also evaluated by a series of in vitro and in vivo experiments.
Results: miR-622 expression level was significantly downregulated in PTC tissues and cell lines. Decreased miR-622 expression was associated with advanced clinical stage and lymph node metastasis (P<0.01). The overexpression of miR-622 in TPC-1 cells inhibited cell proliferation, migration and invasion in vitro, as well as suppress tumor growth in vivo. Moreover, we also demonstrated that miR-622 specifically targeted the 3'-UTR regions of vascular endothelial growth factor A (VEGFA) and inhibited its expression both mRNA level and protein levels. Overexpression of VEGFA reversed miR-622-mediated inhibition effect on cell proliferation, migration and invasion in thyroid cancer cells. More importantly, VEGFA expression was significantly increased and inversely correlated with the levels of miR-622 in PTC tissues.
Conclusion: These results show that miR-622 acts as a tumor suppressor in thyroid cancer, at least in part, via targeting VEGFA, and suggest that miR-622 may serves as a potential target for treatment of thyroid cancer patients.
Keywords: thyroid cancer, miR-622, VEGFA, proliferation, invasion
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]